---
title: "Disc Medicine highlights bitopertin Phase 3 EPP program in corporate presentation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298514743.md"
description: "Disc Medicine highlighted its bitopertin Phase 3 APOLLO program for erythropoietic protoporphyria (EPP) in a recent investor presentation. The trial, enrolling 183 patients, aims for a Q4 2026 readout with endpoints focusing on pain-free sunlight exposure and PPIX reduction. Previous Phase 2 data showed significant efficacy. The company's pipeline also includes selcodebart for anemia and DISC-3405 for polycythemia vera and sickle cell disease."
datetime: "2026-09-09T23:47:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298514743.md)
  - [en](https://longbridge.com/en/news/298514743.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298514743.md)
generator: "portal-rs"
---

# Disc Medicine highlights bitopertin Phase 3 EPP program in corporate presentation

-   Disc Medicine released an investor presentation outlining late-stage plans for bitopertin in erythropoietic protoporphyria, with Phase 3 APOLLO readout expected Q4 2026. \* APOLLO enrolled 183 EPP or XLP patients ages 12+ in a 6-month, randomized, double-blind, placebo-controlled trial using a 60 mg dose. \* Co-primary endpoints target pain-free sunlight exposure in month 6, plus % change in whole-blood metal-free PPIX at 6 months. \* Phase 2 AURORA highlighted a 40% PPIX reduction vs baseline, a 75% drop in phototoxic reactions vs placebo, 86% reporting “much better.” \* Pipeline focus remains heme and iron biology, including selcodebart for anemia indications, plus DISC-3405 for polycythemia vera and sickle cell disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)

## Related News & Research

- [Disc Medicine to Present Phase 2 Selcodebart Data in Myelofibrosis Anemia at ASH](https://longbridge.com/en/news/304291082.md)
- [Disc Medicine (IRON) Nails Phase 3 APOLLO Readout, Is The 34% Undervaluation Still Real?](https://longbridge.com/en/news/304497095.md)
- [Disc Medicine's Q3 net loss narrows on lower R&D expenses](https://longbridge.com/en/news/304465929.md)
- [Disc Medicine Participates in Fireside Chats at Investor Conferences](https://longbridge.com/en/news/303964078.md)
- [BUZZ-Disc Medicine down after $450 mln equity raise following rare disease drug trial success](https://longbridge.com/en/news/302555358.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**